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Summary The effective management of advanced colorectal cancer has traditionally been viewed in terms of treatment outcome measures
such as efficacy (survival, objective response and palliation) and safety. Although these outcomes are of paramount importance and are
essential for the evaluation of the effectiveness and tolerability of treatment, they do not take account of the global effect of therapy on
patients, society and healthcare systems. Furthermore, they may not reveal important differences between treatments of equivalent anti-
tumour efficacy that might influence the overall effectiveness in terms of acceptability of therapy. To achieve this, a broader, patient-centred
evaluation of advanced cancer treatment is required that acknowledges the views, experience and perspectives of all involved in the
treatment process. To this end, the International Working Group in Colorectal Cancer, a multidisciplinary group that encompasses expertise
from a range of relevant fields and disciplines, has advocated a multidisciplinary approach to the treatment of advanced colorectal cancerthat
is likely to deliver the best possible overall care.
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The three major types of therapy in colorectal cancer (CRC) are
surgery, chemotherapy and radiation therapy, each of which is
applied differently depending on whether the aim of treatment is
curative or palliative (i.e. to control symptoms and extend
survival). For example, when used in the curative setting, the
purpose of surgery is to excise completely the tumour;
chemotherapy is used to eradicate micrometastatic disease and
radiation therapy is used to enhance local control ofthe tumour. In
the palliative setting, the tumour may be partly excised to relieve
obstruction, chemotherapy is used to achieve an objective response
or to stabilize the disease andradiotherapy can help toprovidepain
relief and to delay symptomatic progression. Palliative therapy in
advanced gastrointestinal cancer may offer benefits to patients in
terms of improved or maintained performance status, weight gain
and reductions in disease-related symptoms, and may extend
survival compared with best supportive care (Nordic Gastro-
intestinal Tumor Adjuvant Therapy Group, 1992; Pyrhonen et al,
1992; Rougier et al, 1992; Scheithauer et al, 1993; Palmer et al,
1994; Glimelius et al, 1995). The assessment of quality of life
presents a challenge in cancer care, and there are many factors to
be considered, including disease progression, toxicity, inconve-
nience ofsome chemotherapy treatment regimens and loss ofbody
function and image associated with a permanent colostomy.
For the purposes ofthis discussion, advanced CRC is defined as
colorectal cancer that at presentation or recurrence is either
metastatic or so locally advanced that surgical resection is unlikely
to becarried outwith curative intent. Althoughthere are anumberof
end points that may be considered in advanced CRC, the effective
management of this disease has been viewed traditionally in terms
of cure and survival, with the additional end points of objective
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response rate, local control and palliation. These classic outcome
measures have been used to assess treatment success in many
studies published to date. The value ofthese end points to the effec-
tive management ofadvanced CRC is indisputable, and they are an
integral part of the assessment of treatment outcome. However, a
greater appreciation is now being shown of other treatment end
points including stabilization ofdisease, improvements in quality of
life, patient satisfaction and convenience oftreatments for patients,
and the overall cost-effectiveness or cost benefits associated with
therapy. In the past, these outcomes were often considered to be
secondary end points, but they are increasingly being considered by
clinicians and other healthcare providers to be of equal importance
to standard treatment outcomes, such as disease control, survival
and objective response (Donovan et al, 1989; Moinpour et al, 1989;
Redmond, 1997).
The broader approach to the evaluation of the treatment of
advanced CRC, which takes into account the perspectives of all
involved and focuses on the patient's needs and preferences, has
been addressed in recent years by the work of the International
Working Group in Colorectal Cancer (IWGCRC). This is a multi-
disciplinary group that includes representatives from medical,
radiation and surgical oncology, and from nursing and pharmacy.
The objectives of this international working group are to investi-
gate current perceptions of the management of advanced CRC in
France, Germany, Italy, the UK and the USA, and to develop
international recommendations for the multidisciplinary manage-
ment ofadvanced CRC.
DESIGNING THERAPIES TO ENHANCE
PATIENT-CENTRED OUTCOMES
Patients see and exchange information with different members of
the healthcare team at different times, and all members ofthe team
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Figure 1 Incidence of acute toxicity (NCI grade 3+) in 16 patients who
received preoperative and 25 who received post-operative combined modality
therapy in two parallel phase clinical trials. Results were collated for the
highest level of toxicity per patient, with multiple toxicities in the same patient
being scored as a single event. Results expressed as percentages of patients
who were evaluable at each dosage level are shown above each bar (Minsky
et al, 1992a)
need to monitor the results oftreatment and respond appropriately.
The need for more effective liaison between different clinical
disciplines is illustrated by the observation that preoperative radia-
tion therapy or combined modality therapy in patients with rectal
cancer who undergo surgery may be associated with a more
favourable outcome (reduced toxicity and better preservation of
sphincter function) than post-operative therapy (Minsky et al,
1992ci; Rouanet et al, 1995; Hyams et al] 1997; Maghfoor et al,
1997). An example of how patient-centred end-points such as
reduced incidence of acute side-effects and the avoidance of
permanent colostomy might be used to improve the overall effec-
tiveness of treatment is shown by the following data from the
Memorial Sloan-Kettering Cancer Center (Minsky et al, 1992a).
Post-operative radiation plus systemic chemotherapy is the most
effective adjuvant therapy after surgery for transmural and/or
node-positive resectable rectal cancer (Gastrointestinal Tumor
Study Group, 1985; Douglass et al, 1986; Krook et al, 1992).
However, it is also associated with a 25-50% incidence of grade
3+ toxicity. Some advantages of preoperative therapy have been
noted, including increased resectability and increased chance of
sphincter-sparing surgery. A retrospective comparison of two
parallel phase I clinical studies was performed to compare preop-
erative and post-operative adjuvant treatment. In one trial (Minsky
et al, 1991), 16 patients with unresectable rectal cancer received
two cycles of bolus 5-fluorouracil (5-FU) (200-250 mg m-' with
leucovorin 200 mg m-2) plus radiation (total dose of 5040 cGy to
the pelvis) before surgery, followed by a median two further cycles
of chemotherapy after surgery. In the second trial (Minsky et al.
1992b), 25 patients with resectable disease were given the same
regimen, but with all treatments being administered after surgery.
Despite significantly more patients in the preoperative group
than in the post-operative group having received the higher dosage
(250 mg m-2) of 5-FU (75% vs 32%, P = 0.02), the overall inci-
dence of acute grade 3+ toxicity was significantly higher in post-
operative than in preoperative patients (Figure 1). The two grade 3
toxicities in the preoperative patient group were gastrointestinal in
nature, whereas there were seven gastrointestinal and two genito-
urinary toxicity reports, and four grade 4 toxicities, in the post-
operative group. The data illustrate how the overall effectiveness
of a treatment may be augmented to the patient's benefit through
the design of a regimen that minimizes toxicity relative to other
treatment schedules. They also demonstrate the importance of
tolerability as an end point worthy of primary consideration by all
those involved with the care of the patient.
A further example of how treatment can be manipulated to
preserve the patient's quality of life is to be found in several series
of data from non-randomized clinical studies in which therapies
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Figure 2 Effect of preoperative adjuvant radiotherapy (RT) or combined modality therapy (CMT) on patients with operable carcinoma of the rectum. Bars show
the initial sample of patients who were judged clinically by the operating surgeon to require abdominoperineal resection (APR), and the proportions of these
patients who underwent sphincter-sparing surgery subsequent to preoperative adjuvant therapy (Rouanet et al, 1995; Grann et al, 1997; Hyams et al, 1997;
Maghfoor et al, 1997; Wagman et al, 1997)
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Figure 3 A representation of patient-centred multidisciplinary management
in advanced cancer
were designed with the intention ofpreserving sphincter function.
The standard surgical treatment for many distal rectal cancers is
abdominoperineal resection (APR). This procedure involves the
removal ofthe anal sphincter and therefore necessitates the forma-
tion of a permanent colostomy, with consequent deleterious effects
on the patient's body function and image (Williams, 1984;
Rouanet et al, 1993). The traditional rationale for this procedure
lies in the natural history of these tumours, with their high risk of
local recurrence (Domergue et al, 1988), the need for a 2-cm distal
margin (Pollett and Nicholls, 1983; Williams et al, 1983) and the
requirement for complete removal of the perirectal fat (McAnema
et al, 1990; Leo et al, 1993). In recent years, improvements in
surgery and the use ofpreoperative radiation therapy or combined
modality therapy have allowed sphincter preservation in some
patients who respond well to the down-staging effects of neo-
adjuvant therapies.
Data from five studies suggest that preoperative radiation
therapy or combined modality therapy can benefit patients by
making sphincter-preserving surgery possible (Rouanet et al,
1995; Grann et al, 1997; Hyams et al, 1997; Maghfoor et al, 1997;
Wagman et al, 1997). Figure 2 shows patients who were able to
undergo conservative surgery (local excision or a low anterior
resection with or without a coloanal anastomosis) as a result of
having received preoperative adjuvant radiation or combined
modality therapy. In the majority of reports, sphincter-sparing
surgery was made possible in 76-85% of patients who, on the
basis of an examination, werejudged clinically to require an APR
with a permanent colostomy. Had adjuvant therapy not been made
available to these patients, it is likely that all would have required
an APR and associated permanent colostomy. Thus, these findings
have considerable implications for the patient's quality of life,
bodyimage andpsychological well-being. Furthermore, in the two
series reporting sphincter function, it was reported to be 'good' or
'excellent' in 85% (Wagman et al, 1997) and 'perfect' in 71%
(Rouanet etal, 1995) ofevaluable patients. Although the phase I/II
data that suggest thatpreoperative therapy has lower acute toxicity
and enhances sphincter preservation need to be confirmed in a
randomized trial, the results are nonetheless illustrative ofquality-
of-life end points.
PATIENT CONSIDERATIONS AND SOCIAL,
SOCIETAL AND COMMUNITY PERSPECTIVES
The global effect of treatment on the patient is of significant
importance and consists of several overlapping aspects, including
physical distress (e.g. adverse effects oftreatment) and psycholog-
ical stress (e.g. anxiety, depression and problems associated with
body image) (Redmond, 1997). Considerations that are likely to be
of immediate significance to the patient are those relating to
toxicity and inconvenience oftreatment, and loss ofbody function
and image. Common toxicities associated with chemotherapy for
advanced CRC include mucositis, diarrhoea, alopecia, nausea and
vomiting, asthenia and hand-foot syndrome. Inconvenience is
likely to be caused to the patient by frequent hospitalization, loss
of work and family time, difficulties in travelling and compliance
with some modes of administration of chemotherapy (e.g. contin-
uous infusions of 5-FU). The financial difficulties related to
hospital stays, high medication costs or loss of work that can be
caused by cancer treatment are such that the appropriate measure-
ment of costs incurred by the patients is an issue in itself in the
economic evaluation of cancer treatment (Bonsel et al, 1993).
Patients also experience the damaging psychological effects of
loss of body image when faced with the possibility of loss of
sphincter function in rectal cancer and the prospect of stoma care.
There are also social, societal and community-related perspec-
tives to consider in anti-cancer therapy. These issues tend to be
neglected by physicians and include the stresses on the patient as
described earlier. Families and close friends may experience the
negative aspects of cancer treatment, which include financial
factors, social isolation and stress, in a similar way to the patient.
These are all issues relevant to the discussion ofquality-of-life end
points and the overall implications of treatment of advanced CRC.
Anti-cancer treatments also have a major impact on medical and
nursing workloads: two regimens might be similar in efficacy but
might differ in their adverse effect profiles and complexity and
frequency of delivery. Effective communication across medical,
surgical and paramedical disciplines and with patients is needed to
identify treatments that are more convenient to deliver and
manage.
A PATIENT.CENTRED MULTIDISCIPLINARY
MANAGEMENT MODEL
Using the patient-centred multidisciplinary management model,
the patient is considered as being at the centre of a continual
process (patient-centred) that starts at diagnosis and ends, for all
patients with advanced disease, in death. Components that feed
into this therapeutic process are shown in Figure 3. General practi-
tioners and patient support services are pictured against the patient
to show their continuing presence and input from beginning to
end. Other practitioners, including medical and radiation oncolo-
gists, surgeons and oncology nurses sometimes have contact with
the patient for only relatively short and discrete periods after diag-
nosis, and there is therefore a tendency to neglect the need for
continual and ongoing care and support. Ideally, all disciplines
should operate together as a single unit, with the patient at the
centre ofthe treatment process at all times.
This process benefits both patients and care providers, with the
interprofessional exchange of information being of particular
value to physicians who prescribe treatment. The economic, social
and societal impact ofeach treatment should also be assessed. The
multidisciplinary approach to the management of patients with
advanced CRC addresses important treatment end points that tend
to be overlooked, although they are, according to the patient-
centred model, as important as survival. These include tolerability,
quality of life and patient satisfaction. Thus, in the assessment of
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therapy for advanced CRC, patient satisfaction with treatment is a
goal. There is a wide range of outcomes to be considered, and
accurate quality-of-life information (if available) makes a major
contribution to improving the management of these patients
(Donovan et al, 1989). The IWGCRC has recommended the adop-
tion of the multidisciplinary approach to deliver the best overall
evaluations and subsequent outcomes for patients. Furthermore, it
has identified the need for and the composition of the multidisci-
plinary team, has put forward international treatment recommen-
dations and is currently discussing the development of tools to
assist with the assessment ofpatient satisfaction.
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